WO2000036420A3 - Expression differentielle dans le cas du cancer primaire du sein - Google Patents

Expression differentielle dans le cas du cancer primaire du sein Download PDF

Info

Publication number
WO2000036420A3
WO2000036420A3 PCT/GB1999/004183 GB9904183W WO0036420A3 WO 2000036420 A3 WO2000036420 A3 WO 2000036420A3 GB 9904183 W GB9904183 W GB 9904183W WO 0036420 A3 WO0036420 A3 WO 0036420A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
primary breast
breast cancer
differential expression
tumour
Prior art date
Application number
PCT/GB1999/004183
Other languages
English (en)
Other versions
WO2000036420A2 (fr
Inventor
Alan Gordon Mackay
Michael John O'hare
Original Assignee
Ludwig Inst Cancer Res
Alan Gordon Mackay
Hare Michael John O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Alan Gordon Mackay, Hare Michael John O filed Critical Ludwig Inst Cancer Res
Priority to EP99959579A priority Critical patent/EP1137944A2/fr
Publication of WO2000036420A2 publication Critical patent/WO2000036420A2/fr
Publication of WO2000036420A3 publication Critical patent/WO2000036420A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé permettant d'identifier des séquences nucléotidiques qui ont une expression différentielle dans des cellules tumorales, de préférences de cellules tumorales primaires du sein. Ce procédé consiste à prendre un échantillon tissulaire contenant une cellule tumorale et à l'exposer à un agent spécifique de la protéine d'activation du fibroblaste (FAP), à séparer du reste des cellules de l'échantillon les cellules reconnues par cet agent, et à récolter ces cellules restantes. L'invention concerne également, d'une part des molécules d'acides nucléiques découlant de l'utilisation de cette technique, d'autre part des compositions les comprenant, et enfin leurs utilisations.
PCT/GB1999/004183 1998-12-11 1999-12-10 Expression differentielle dans le cas du cancer primaire du sein WO2000036420A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP99959579A EP1137944A2 (fr) 1998-12-11 1999-12-10 Expression differentielle dans le cas du cancer primaire du sein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9827430.1 1998-12-11
GBGB9827430.1A GB9827430D0 (en) 1998-12-11 1998-12-11 Differential expression in primary breast cancer

Publications (2)

Publication Number Publication Date
WO2000036420A2 WO2000036420A2 (fr) 2000-06-22
WO2000036420A3 true WO2000036420A3 (fr) 2000-10-19

Family

ID=10844141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/004183 WO2000036420A2 (fr) 1998-12-11 1999-12-10 Expression differentielle dans le cas du cancer primaire du sein

Country Status (3)

Country Link
EP (1) EP1137944A2 (fr)
GB (1) GB9827430D0 (fr)
WO (1) WO2000036420A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008044957A1 (fr) * 2006-10-09 2008-04-17 Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) Procédé d'analyse différentielle de protéomes
EP3555627B1 (fr) 2016-12-14 2023-11-22 Purdue Research Foundation Imagerie et thérapie ciblées par une protéine d'activation des fibroblastes (fap)
CN107988160A (zh) * 2018-01-11 2018-05-04 武汉大学深圳研究院 人乳腺癌细胞及其原代分离培养和传代培养方法与用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005804A1 (fr) * 1991-09-18 1993-04-01 Sloan-Kettering Institute For Cancer Research Anticorps f19 specifique contre les fibroblastes stromals actives et procedes pour son utilisation
EP0584715A2 (fr) * 1992-08-26 1994-03-02 Dr. Kübler GmbH Isolation et cultivation de cellules transformées et procédure de préparation des anticorps contre ces cellules
WO1994014977A1 (fr) * 1992-12-22 1994-07-07 Merck Frosst Canada Inc. Adn complementaire de cyclo-oxygenase-2 humaine et titrage permettant d'evaluer l'inhibition de la cyclo-oxygenase-2
WO1994025852A1 (fr) * 1993-04-26 1994-11-10 Coulter Corporation Procede d'analyse de la teneur en adn de cellules tumorales par enrichissement en cellules tumorales
WO1997030065A1 (fr) * 1996-02-16 1997-08-21 Millennium Pharmaceuticals, Inc. Compositions et procedes de traitement et de diagnostic des maladies cardio-vasculaires
WO1997038085A2 (fr) * 1996-04-10 1997-10-16 California Pacific Medical Center Genes amplifies dans des cellules cancereuses
WO1998033915A1 (fr) * 1997-02-03 1998-08-06 Human Genome Sciences, Inc. Gene 1 specifique du cancer du sein
WO1999025843A2 (fr) * 1997-10-22 1999-05-27 The Scripps Research Institute Kinase humaine de controle, hcds1, compositions et procedes

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005804A1 (fr) * 1991-09-18 1993-04-01 Sloan-Kettering Institute For Cancer Research Anticorps f19 specifique contre les fibroblastes stromals actives et procedes pour son utilisation
EP0584715A2 (fr) * 1992-08-26 1994-03-02 Dr. Kübler GmbH Isolation et cultivation de cellules transformées et procédure de préparation des anticorps contre ces cellules
WO1994014977A1 (fr) * 1992-12-22 1994-07-07 Merck Frosst Canada Inc. Adn complementaire de cyclo-oxygenase-2 humaine et titrage permettant d'evaluer l'inhibition de la cyclo-oxygenase-2
WO1994025852A1 (fr) * 1993-04-26 1994-11-10 Coulter Corporation Procede d'analyse de la teneur en adn de cellules tumorales par enrichissement en cellules tumorales
WO1997030065A1 (fr) * 1996-02-16 1997-08-21 Millennium Pharmaceuticals, Inc. Compositions et procedes de traitement et de diagnostic des maladies cardio-vasculaires
WO1997038085A2 (fr) * 1996-04-10 1997-10-16 California Pacific Medical Center Genes amplifies dans des cellules cancereuses
WO1998033915A1 (fr) * 1997-02-03 1998-08-06 Human Genome Sciences, Inc. Gene 1 specifique du cancer du sein
WO1999025843A2 (fr) * 1997-10-22 1999-05-27 The Scripps Research Institute Kinase humaine de controle, hcds1, compositions et procedes

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL (EMEST) EMBL. Heidelberg; 9 May 1996 (1996-05-09), HILLIER L. ET AL.: "The WashU-Merck EST project", XP002136148 *
DATABASE EMEST24 EMBL, Heidelberg; 15 March 1997 (1997-03-15), STRAUSBERG R.: "National Cancer Institute, Cancer genome anatomy project (CGAP), tumor gene index", XP002136152 *
DATABASE EMEST27 EMBL, Heidelberg; 27 April 1996 (1996-04-27), HILLIER L. ET AL.: "The WashU-Merck EST project", XP002136150 *
DATABASE EMEST28 EMBL, Heidelberg; 26 January 1997 (1997-01-26), HILLIER L. ET AL.: "The WashU-Merck EST project", XP002136153 *
DATABASE EMEST5 EMBL, Heidelberg; 8 May 1998 (1998-05-08), STRAUSBERG R.: "National Cancer Institute, Cancder genome anatomy project (CGAP), tumor gene index", XP002136151 *
DATABASE EMETS4 EMBL, Heidelberg; 9 April 1998 (1998-04-09), R. STRAUSBERG: "National Cancer Institute, cancer genome anatomy project (CGAP), tumor gene index", XP002136147 *
DATABASE EMHUM1 EMBL, Heidelberg; 11 December 1998 (1998-12-11), MATSUOKA S. ET AL., XP002136297 *
DATABASE EMHUM1 EMBL, Heidelberg; 16 February 1998 (1998-02-16), ISHIBASHI K. ET AL., XP002136286 *
DATABASE EMHUM3 EMBL, Heidelberg; 8 January 1993 (1993-01-08), BACHMANN M.P.: "One gene, two transcripts: isolation of an alternative transcript encoding for the autoantigen La/SS-B...", XP002136287 *
DATABASE EMHUM4 EMBL, Heidelberg; 17 June 1993 (1993-06-17), HONG J.X. ET AL., XP002136149 *
DATABASE GENESEQ Derwent, UK; 16 August 1999 (1999-08-16), BLASINA A. ET AL.: "New human kinase used for treatment of cancer and proliferative diseases", XP002136154 *
DATABASE GENESEQ Derwent; 27 February 1995 (1995-02-27), WONG E.: "Assays for cyclooxygenase-1 and -2, for identifying selective antagonists...", XP002134573 *
HONG J.X. ET AL.: "Isolation and characterisation of a novel B cell activation gene", J.IMMUNOLOGY, vol. 150, no. 9, 1993, US, pages 3895 - 3904, XP002126588 *
ISHIBASHI K. ET AL.: "Cloning and functional expression of a new aquaporin (AQP9) abundantly expressed in the perypheral leukocytes permeable to water and urea, but not to glycerol", BIOCHEMICAL BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 244, 1998, pages 268 - 274 *
MATSUOKA S. ET AL.: "Linkage of ATM to cell cycle regulation by the Chk2 protein kinase", SCIENCE, vol. 282, 4 December 1998 (1998-12-04), USA, pages 1893 - 1897, XP002922301, DOI: doi:10.1126/science.282.5395.1893 *
SLAMON D J ET AL: "STUDIES OF THE HER-2/NEU PROTO-ONCOGENE IN HUMAN BREAST AND OVARIANCANCER", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 244, no. 4905, 12 May 1989 (1989-05-12), pages 707 - 712, XP002019974, ISSN: 0036-8075 *
WATSON M A ET AL: "ISOLATION OF DIFFERENTIALLY EXPRESSED SEQUENCE TAGS FROM HUMAN BREAST CANCER", CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 54, 1 September 1994 (1994-09-01), pages 4598 - 4602, XP002019977, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
EP1137944A2 (fr) 2001-10-04
GB9827430D0 (en) 1999-02-03
WO2000036420A2 (fr) 2000-06-22

Similar Documents

Publication Publication Date Title
DE69632466D1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
Matsumoto et al. Evidence for the involvement of H1 histone phosphorylation in chromosome condensation
AU7222698A (en) Method of preparing a standard diagnostic gene transcript pattern
DE60045796D1 (de) Gesamt-chromosom analyse von protein-dns wechselwirkungen
WO2000024365A8 (fr) Traitement de la peau au moyen d'adenosine ou d'un analogue d'adenosine
WO2000052204A3 (fr) Expression genique dans les tumeurs de la vessie
WO1999064576A3 (fr) Nouveaux genes humains et produits d'expression genique
EP0779365A3 (fr) Méthodes pour introduire de l'acide nucléique dans des cellules pour applications thérapeutiques et diagnostiques
EP0790312A3 (fr) Vecteurs spécifiques pour l'insertion de gènes dans des cellules cibles, médicament contenant lesdits vecteurs et leur utilisation
DE69906977D1 (de) In liposomen verkapselte nukleinsäurekomplexe
AU9125198A (en) Compositions, kits, and methods for effecting adenine nucleotide modulation of dna mismatch recognition proteins
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
AU6380001A (en) Porous ferro- or ferrimagnetic glass particles for isolating molecules
ATE338821T1 (de) Strukturprotein von aav, seine herstellung und verwendung
WO1997025416A3 (fr) Nouvelles glycosylases d'adn et leur utilisation
WO2000026666A3 (fr) Caracterisation de cellules individuelles par des marqueurs multiples
WO2003020877A3 (fr) Coloration et tri de genomes et de chromosomes au moyen de polyamides specifiques de sequences
WO1998035554A3 (fr) Combinaison therapie genique suppressive de tumeurs - chimiotherapie utilisee dans le traitement de neoplasmes
Edström et al. Ribonucleotide analysis of individual nerve cells
Ramsey et al. Differences in size, structure and function of free and membrane-bound polyribosomes of rat liver. Evidence for a single class of membrane-bound polyribosomes
WO2000036420A3 (fr) Expression differentielle dans le cas du cancer primaire du sein
DE69714775D1 (de) Verfahren zur Tötung von Zielzellen in geernteten Zellpopulationen mit Hilfe von zwei Immunotoxinen
WO2000008157A3 (fr) Genes humains transporteurs d'anions atnov
AU3045189A (en) Determination of genetic sex in ruminants using y-chromosome-specific polynucleotides
WO1997015668A3 (fr) Procedes et compositions comprenant glut-2 et des chimeres de glut-2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CN JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999959579

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09857740

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999959579

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999959579

Country of ref document: EP